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Bacterial DNA and synthetic cytidine–phosphate–guanosine–oligodeoxynucleotides (CpG ODN) potently activate
dendritic cells (DC) and therefore have been proposed as adjuvants for vaccination strategies. Although CpG ODN are
considered as safe adjuvants this study shows that CpG ODN are responsible for enhanced antigen-specific skin
inﬂammatory reactions. We used the murine model of contact hypersensitivity (CHS) to 2,4-dinitroﬂuorobenzene
(DNFB) in which hapten-specific CD8þT cytotoxic 1 cells are effector cells. Subcutaneous injection of CpG ODN, 1 d
before sensitization enhanced the CHS response to DNFB and resulted in increased recruitment of CD8þ T cells at the
challenge sites, whereas control ODN injection did not have any effect. This effect was local and not systemic as it was
only observed when DNFB was applied at the same site as the CpG motifs. CpG ODN-induced enhancement of CHS
was due to increased antigen-presenting cell functions of DC since: (i) CpG ODN-injected skin revealed upregulated
expression of major hisotcompatibility complex class II, CD80, and CD86 molecules and (ii) CpG ODN treatment of
DNFB-derivatized DC enhanced the intensity of CHS responses after in vivo transfer. Taken together, the results show
that CpG ODN may be responsible for immune side-effects such as worsening of T cell-mediated skin diseases.
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DNA vaccination is based on in vivo transfection of host
cells with a bacterial DNA plasmid encoding the antigen of
interest. Immunizations with plasmid DNA promote effective
immune responses against many bacteria, virus, and par-
asites in rodents (Donnelly et al, 1997; Kaiserlian and Et-
chart, 1999). Part of this effectiveness is due to the
immunostimulatory effect of unmethylated bacterial DNA
itself. Specific nucleotide immunostimulatory sequences,
including unmethylated cytidine–phosphate–guanosine
oligodeoxynucleotides (CpG ODN), are responsible for the
Th 1 response generated after intradermal immunization of
naked DNA, inasmuch as they suppress IgE production but
promote IgG and IFN-g production (Sato et al, 1996). They
further initiate the production of IFN-b, IL-12, and IL-18, all
of which foster Th 1 responses and enhance cell-mediated
immunity (Krieg et al, 1995; Roman et al, 1997; Yi and Krieg,
1998), revealing the therapeutic potential of CpG DNA as
adjuvants for vaccination strategies in cancer, allergy, and
infectious diseases (Weiner, 2000a, b).
In contrast to their beneficial properties, CpG ODN may
have harmful side-effects. CpG motifs may play a role in the
etiology of a variety of diseases such as systemic lupus
erythematosus and sepsis syndrome (Goldberg et al, 2000)
and could worsen experimental allergic encephalomyelitis,
an autoimmune demyelinating disease used as an animal
model of multiple sclerosis (Tsunoda et al, 1999). Moreover,
daily administration of CpG ODN in mice is responsible for
immunotoxic and hepatotoxic effects occurring as early as
day 7 of treatment (Heikenwalder et al, 2004). Because the
skin is the site of administration of CpG ODN, it is likely that
their use could influence the outcome of antigen-specific
skin inflammatory diseases. But so far, no study has ad-
dressed this question and the potential cutaneous side-
effects of CpG ODN are still unknown.
Contact hypersensitivity (CHS), the experimental model
of human contact dermatitis, is a type IV delayed-type
hypersensitivity (DTH) to haptens applied epicutaneously
and is mediated by antigen-specific T cells (Grabbe and
Schwarz, 1998; Krasteva et al, 1999a, b). The pathophys-
iology of CHS consists classically of two distinct phases
(Enk and Katz, 1992; Krasteva et al, 1999a): (i) the afferent
phase (also referred to as the sensitization phase) occurs at
the first contact of skin with the hapten. Skin dendritic cells
(DC) uptake the hapten and migrate to the draining lymph
nodes, where they present haptenated peptides to T cells
(Lepoittevin and Leblond, 1997), resulting in the induction
of hapten-specific effector and regulatory T cells; (ii) the
efferent phase (also known as elicitation phase) induced by
epicutaneous challenge with the same hapten in sensitized
individuals leads in, a few hours, to the recruitment in the
skin of effector T cells leading to skin inflammation. In CHS
to the strong hapten 2,4-dinitrofluorobenzene (DNFB),
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CD8þ T cytotoxic 1 (Tc 1) cells are effectors and induce
skin inflammation through cytotoxicity and keratinocyte
apoptosis (Kehren et al, 1999; Akiba et al, 2002), whereas
CD4þ T cells behave as regulatory cells (Bour et al, 1995;
Krasteva et al, 1998; Dubois et al, 2003).
The aim of this study was to test for the effect of CpG
ODN treatment on the development of the CHS reaction to
DNFB, more so since recent studies revealed that, upon
antigen priming, CpG ODN could induce the preferential
differentiation of antigen-specific CD8þ T cells into Tc 1
effectors (Tascon et al, 2000). We show here that CpG ODN
treatment is able to increase the CHS reaction to DNFB by
increasing the antigen-presenting cell functions of skin DC.
These results suggest that the CpG ODN could worsen an-
tigen-specific T cell responses in the skin.
Results
CpG ODN enhance CHS when applied at the site of
DNFB sensitization CHS to DNFB was performed by ep-
icutaneous sensitization on the back skin at day 0 and
challenge on the ear at day 5. CHS was tested in groups of
mice, which received one subcutaneous (s.c.) injection of
CpG ODN, control ODN, or PBS alone, on the back or on
abdominal skin 1 d before DNFB sensitization. Two groups
of mice were depleted in CD8þ T cells by in vivo treatment
with anti-CD8 mAb.
When mice received CpG ODN at the same site as the
DNFB sensitization, i.e., the back skin, the intensity of CHS
to DNFB was enhanced compared with that observed in
mice receiving control ODN or PBS alone (Fig 1). But the
kinetics of the CHS reaction was similar in the three groups
of mice with a maximal ear swelling at 24/48 h. Downreg-
ulation of the inflammation started at day 3 and complete
recovery was achieved at days 10–15. In vivo treatment of
mice before the sensitization phase with anti-CD8 mAb, but
not control isotype mAb, depleted the CD8þ T cell subset
(data not shown) and abrogated the CHS reaction, con-
firming that CD8þ T cells mediate the CHS reaction to
DNFB. Alternatively, when mice received CpG ODN injec-
tions at a skin site distant from the sensitization site, i.e., the
abdominal skin, CHS reaction was not affected by CpG
ODN treatment. The magnitude of the CHS response was
similar in both CpG ODN (abdomen)- and control ODN
(back)-treated mice (Fig 1). These data show that CpG ODN
function as a local, but not systemic, adjuvant for enhance-
ment of contact hypersensitivity to DNFB in mice.
CpG ODN-treated mice develop enhanced recall T cell
responses We next analyzed the mechanisms of the local
adjuvant effect of CpG ODN. First, we examined whether
CpG ODN could increase the immunological memory to hap-
tens. CpG ODN- and control ODN-treated mice which had
developed a CHS response by hapten painting on the left ear
on day 5 (as in Fig 1) were both re-challenged on day 28 on
the right ear with DNFB. The recall CHS reaction was signif-
icantly enhanced in previously CpG ODN-treated mice com-
pared with control ODN-treated mice (Fig 2), demonstrating
the stimulatory effect of CpG ODN on T cell responses.
CpG ODN treatment increases CD8þ T cell inﬁltration in
challenged skin Since CHS to DNFB is mediated by infil-
tration of IFN g-producing CD8þ effector T cells in the ep-
idermis at the challenge site (Akiba et al, 2002), we next
analyzed the contribution of CD8þ T cell recruitment to the
enhanced CHS response observed in CpG ODN-treated
mice. Ears from control ODN- and CpG ODN-treated mice
were recovered 24 h after challenge at the peak of the CHS
reaction. Histological analysis showed increased dermal
edema and mononuclear cell infiltration in CpG ODN-
compared with control ODN-treated mice (Fig 3A, B).
Immunohistochemical analysis revealed that in control
ODN-treated mice, CD8þ cells were mostly found in the
upper dermis with a few CD8þ epidermal cells. Although
there was a slight increase in CD8þ cell infiltration in the
dermis of CpG ODN-treated mice compared with control
ODN-treated mice, CpG ODN-treated mice exhibited much
higher numbers of CD8þ cells infiltrating the epidermis
(Fig 3C–E). That CD8þ epidermal cells were T cells was
confirmed by additional experiments showing that they ex-
pressed CD3 but not major histocompatibility complex
(MHC) class II molecules (data not shown).
We next examined the presence of CD8 and IFN-gmRNA
in the ears of mice treated with CpG ODN or control ODN
24 h after challenge and subjected to mRNA extraction and
Figure1
Effect of cytidine–phosphate–guanosine–oligodeoxynucleotides
(CpG ODN)-treatment on the contact hypersensitivity (CHS) reac-
tion to 2,4-dinitrofluorobenzene (DNFB). CHS to DNFB was per-
formed by sensitization on the back skin at day 0 and challenge on the
ear at day 5. One day before DNFB sensitization, mice (5 mice per
group) received either one subcutaneous (s.c.) injection of CpG ODN
(’), control ODN (  ), or PBS alone (m) on the back skin. Two groups of
mice receiving CpG (&) and control ODN (  ) were depleted in CD8þ
Tcells by in vivo treatment with anti-CD8 mAb. One group received CpG
ODN treatment on the abdominal skin (abdomen (E)). One group was
left unsensitized and challenged at day 5 ( 4 ). Results are expressed
as the mean ear swelling  SD at different time points after challenge. p
(o0.05) indicates statistical significance between CpG- and control
ODN-treated mice. Results show one representative experiment of four.
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semi-quantitative RT-PCR analysis using HPRT mRNA as
internal standard (Fig 4). CD8 and IFN-g mRNA in the skin
from CpG ODN-treated mice were 1.5–2 times higher than
that of control ODN-treated mice.
Thus, increased CHS response in CpG ODN-treated
mice is associated with enhanced infiltration of IFN-g-pro-
ducing T cells in challenged skin.
CpG ODN induces in vivo activation of epidermal
DC Since CHS reaction is mediated by T cells which are
primed in draining lymph nodes by hapten-bearing DC that
migrate from the skin, we analyzed the effect of CpG ODN
on epidermal DC phenotype and function. In order to test
for the effect of CpG ODN on the expression of MHC and
costimulatory molecules by skin DC, CpG ODN (or control
ODN) was injected intradermally in the right ear of naı¨ve
mice 24 h before epicutaneous application of a sensitizing
dose of 0.5% of DNFB onto the same ear. Ears were re-
covered 24 h after hapten application and analyzed for ex-
pression of DC surface molecules. We observed a more
pronounced upregulation of MHC class II molecules and
increased numbers of CD80þ and CD86þ cells in the ep-
idermis of CpG ODN-injected skin, compared with control
ODN-injected skin (Fig 5A–F) with a 2-fold increase in the
number of CD80þ and CD86þ cells, respectively (Fig 5G).
Next, we tested for the functions of CpG ODN-treated
skin DC. DC recovered from the skin of normal mice were
treated in vitro with CpG ODN, control ODN or left untreat-
ed, and then hapten derivatized by incubation with 2,4-
dinitrobenzenesulfonic acid (DNBS) before s.c. transfer into
naı¨ve mice. Five days later, mice were ear-challenged with
DNFB. As shown in Fig 6, control ODN-treated skin DC
induced a CHS response upon transfer into naı¨ve mice.
Similar results were obtained with untreated, hapten-deri-
vatized skin DC. More importantly, the CHS response in-
duced by adoptive transfer of CpG ODN-treated skin DC
was strongly increased compared with that induced by
control ODN-treated skin DC, demonstrating that CpG ODN
enhanced the immunostimulatory function of skin DC.
Discussion
CHS reaction to DNFB is mediated by antigen-specific,
MHC class I-restricted CD8þ T cells which are induced in
lymphoid organs by presentation of haptenated peptides by
skin DC (Krasteva et al, 1999a; Cavani et al, 2001). Here we
show that CpG ODN can enhance CHS responses by in-
creasing the immunostimulatory properties of skin DC lead-
ing to optimal priming of T cells and increased recruitment
of CD8þ T cells in the skin. This study extends to haptens
previous results obtained with protein antigens and pep-
tides indicating that CpG ODN-based vaccines can aug-
ment T cell responses to specific antigens (Sun et al, 1998)
and promote priming and differentiation of CD8þ T cells
(Tascon et al, 2000; Vabulas et al, 2000).
Our results are consistent with CpG motifs activating skin
innate immunity (Kobayashi et al, 1999; Revillard, 2002)
thereby leading to a more robust effector T cell response.
We show that CpG ODN-induced phenotypic and functional
maturation of skin DC with in vivo upregulation of MHC
class II, CD80, and CD86 surface molecules at sites of
Figure 2
Effect of cytidine–phosphate–guanosine–oligodeoxynucleotides
(CpG-ODN) treatment on the recall contact hypersensitivity (CHS)
response. Mice which developed the CHS response after treatment on
the sensitization site with CpG ODN (A) or control ODN (B), or after
treatment on a distant site with CpG ODN (C) (as in Fig 1) were re-
challenged at day 28 with 2,4-dinitrofluorobenzene (DNFB) on the
contra-lateral ear. One group of unsensitized naı¨ve mice received DNFB
on the ear at day 28 (D). Results are expressed as the mean ear swell-
ing  SD 48 h after the second challenge. p (o0.05) indicates statis-
tical significance between CpG- and control ODN-treated mice. Results
show one representative experiment of three.
Figure3
Histological analysis of the contact hypersensitivity (CHS) reaction
to 2,4-dinitrofluorobenzene (DNFB) in cytidine–phosphate–guano-
sine–oligodeoxynucleotides (CpG ODN)-treated mice 24 h after
challenge. (A, B): Hematoxylin and eosin (H&E) staining of the ear of
control ODN-treated mice (A) and CpG ODN-treated mice (B). Arrow-
head indicates a dilated capillary vessel. (C, D): Immunohistochemical
staining of CD8þ T cells (CD8) in the skin of control ODN-treated (C)
and CpG ODN-treated (D) mice. CD8þ T cells are found in the dermis
in both groups of mice but are found in higher numbers in the epidermis
of CpG ODN-treated mice (arrowheads). Dotted line represents the
dermal–epidermal (D–E) junction. Bar¼20 mm. c, cartilage; e, epider-
mis; d, dermis. (E) Semi-quantitative analysis of CD8þ cells in the
epidermis of control ODN and CpG ODN-treated mice at 24-h post-
challenge. Results are expressed as the mean number of cells per mm
of D–E junction  SD. p (o0.05) indicates statistical significance be-
tween CpG- and control ODN-treated mice. Results show one repre-
sentative experiment of three.
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subcutaneous injection. Furthermore, immunization of naı¨ve
mice by CpG ODN-treated, hapten-derivatized skin DC re-
sulted in enhanced CHS reaction. Finally, the adjuvant effect
of CpG ODN was local but not systemic as: (i) activation of
skin DC and upregulation of costimulatory molecules was
observed at sites of CpG ODN injections but not at distant
sites; (ii) enhanced CHS reaction was obtained when the
hapten was administered at the CpG ODN-injected skin site
but not when applied at sites distant from CpG ODN-in-
jected skin. These data are in line with studies showing that
skin DC are the main target of immunostimulatory DNA
sequences (Vogel and Udey, 2000) through interaction with
toll-like receptor (TLR)-9 (Hemmi et al, 2000) leading to mi-
gration and phenotypic and functional maturation of resi-
dent DC (Jakob et al, 1998, 1999; Ban et al, 2000).
Differences in CpG reactivity between mouse and human
models have been documented. Therefore, it cannot be
concluded from these data that CpG ODN could worsen
CHS in humans. Follow-up of side-effects during clinical
studies on the therapeutic potential of CpG DNA as adjuv-
ants for vaccination strategies in cancer, allergies, and in-
fectious diseases have concluded that CpG motifs were
safe (Weiner, 2000a, b). Moreover, in patients receiving
repeated immunizations with vaccine mixed with CpG, no
significant local hypersensitivity reactions have been re-
ported to date (Halperin et al, 2003).
From this study, it is clear that CpG ODN could cause
adverse cutaneous immune-mediated effects such as en-
hanced CHS reactions. This result was not unexpected
since stimulation of TLR-9 is known to enhance CD8þ CTL
responses, as does CpG (Schwarz et al, 2003). Thus, the
potential side-effects of CpG ODN are directly linked to their
immune properties, i.e., adjuvanticity, with activation of skin
innate immunity to increase the adaptive immune respons-
es. Although the lack of systemic effect of CpG ODN ob-
served in this study would appear to be encouraging, future
clinical studies will have to rule out the possibility that CpG
ODN could cause aggravation of skin diseases, especially
those where antigen-specific T cells are continuously acti-
vated by antigen-bearing skin DC.
Figure 4
RT-PCR analysis of CD8 and IFN-c mRNA expression in the skin
during the contact hypersensitivity (CHS) response. Expression of
CD8 and IFN-g mRNA was determined by semi-quantitative RT-PCR
analysis, 24 h after challenge with 2,4-dinitrofluorobenzene (DNFB) or
vehicle, in the ears of cytidine–phosphate–guanosine–oligodeoxynuc-
leotides (CpG ODN) or control ODN-treated mice (A). Histogram de-
rived from the results presented in A showing the CD8 and IFN-gmRNA
relative quantities expressed as a ratio between optical densities (OD)
obtained in experimental samples compared with HPRT mRNA as
standard (B). Results are representative of four experiments.
Figure5
Immunohistochemical analysis of epidermal cells 24 h after 2,4-
dinitrofluorobenzene (DNFB) sensitization at the site of cytidine–
phosphate–guanosine (CpG) treatment. Mice received subcutaneous
(s.c.) injections of control (A–C) or CpG ODN (D–F) on the ear skin at
day 0, and DNFB painting at day 1. Skin was recovered 24 h after DNFB
painting and cryostat sections were stained for major histocompatibility
complex class II (A, D), CD80 (B, E), and CD86 (C, F) antigen expression
using specific mAbs. Arrows in B, C, E, and F show positive epidermal
cells. Bar¼10 mm. (G) Semi-quantitative analysis of CD80- and CD86-
positive epidermal cells in control ODN- (white bars) and CpG ODN-
(black bars) treated mice. Results are expressed as the mean number
of cells per mm of dermal–epidermal (D–E) junction  SD. p (o0.05)
indicates statistical significance in the results obtained in control versus
CpG-treated mice. Results are representative of three experiments.
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Materials and Methods
Reagents Phosphorothioate-stabilized oligodeoxynucleotides
(ODN) were synthesized and purified under sterilized condition by
Grainer Japan (Tokyo, Japan), and reconstituted in endotoxin-free
water. The ODN sequences used in this study were as follows:
CpG ODN (1668 ODN): 50-TCCATGACGTTCCTGATGCT-30, and
control ODN (1720 ODN): 50-TCCATGAGCTTCCTGATGCT-30 (Krieg
et al, 1995). DNFB (Sigma, St Louis, Missouri) was diluted in ac-
etone:olive oil (4:1) immediately before use. DNBS (Kanto Chem-
ical, Tokyo, Japan) was used for in vitro pulsing of DC. Antibodies
used in in vivo experiments comprised anti-CD8 mAb, produced
by the hybridoma H 35.17.2 kindly provided by G. Milon (Institut
Pasteur Paris) and an isotype control mAb, produced by the hy-
bridoma GL113 (rat anti-b-galactosidase IgG) (ATCC, Manassas,
Virginia). The culture medium used was RPMI 1640 (Gibco BRL,
Grand Island, New York) supplemented with 10% fetal calf serum
(FCS), 100 U per mL penicillin, 100 mg per mL streptomycin (Gibco
BRL), and 2.5 mg per mL Fungizone (Gibco BRL). This was referred
to as complete medium (CM).
Mice Female BALB/C mice (5–8-wk old) were purchased from
SLC (Shizuoka, Japan) and bred in a conventional animal facility.
All animal experiments were performed following the guidelines of
the Fukushima Medical University School of Medicine animal care
and use committee (K01153).
ODN treatment of mice Twenty micrograms of CpG ODN or of
control ODN diluted in PBS were injected subcutaneously (s.c.) in
the back or abdominal skin (total volume of 300 mL) of groups of
BALB/C mice 1 d before epicutaneous application of DNFB at the
back skin. One group of mice received PBS alone and was used as
control.
Induction of contact sensitivity The procedure used is the
‘‘mouse ear swelling test’’ (MEST) which has been described in
detail elsewhere (Garrigue et al, 1994). Briefly, 25 mL of 0.5% DNFB
was applied to the shaved back skin. Five days later, mice were
challenged by applying 10 mL of 0.2% DNFB on both sides of one
ear, and 10 mL of vehicle on the contra-lateral ear. Some groups of
mice were re-challenged, on the opposite ear, 28 d after the first
challenge. Ear thickness was measured with calipers (Peacock,
Tokyo, Japan) prior to challenge, and every day after challenge. Ear
swelling was calculated by the following formula: Ear swell-
ing¼ (ear thickness after challenge with DNFBear thickness be-
fore challenge with DNFB)(ear thickness after challenge with
vehicleear thickness before challenge with vehicle).
Antibody depletion of CD8þ T cells in vivo Mice were given
intraperitoneally (i.p.), injections of 200 mL 1:10-diluted anti-CD8
mAb ascites (mAb concentration, 0.8 mg per mL) or i.p. injections
of 200 mL 1:10-diluted control mAb (mAb concentration, 1.2 mg per
mL) on days 1, 0, þ 1, and þ 4 of skin sensitization. Cell deple-
tion was assessed at days þ 1 and þ 4 by staining CD8 molecules
on peripheral blood mononuclear cell recovered from retro-orbital
plexus. In all cases, specific depletion exceeded 95% on both days.
Skin DC isolation Skin DC were recovered from mouse skin as
previously described (Ortner et al, 1996). Briefly, murine ears were
rinsed in 70% ethanol, and divided in half with forceps. Dorsal
cartilage-free sides were cultured in 24-well tissue culture plates
with dermal side down. The tissues were transferred onto culture
wells with fresh medium every day. On day 3, all cells present in the
culture medium were pooled. Analysis of the cell suspension
showed that 480% of cells which have migrated out of the skin
into the culture medium had a DC morphology and expressed a
high level of MHC class II molecules.
Immunization of naı¨ve mice with ODN-treated, hapten-derivati-
zed skin DC Skin DC were incubated in CM containing CpG ODN
(1 mM), control ODN (1 mM) or left untreated for 12 h at 371C. After
extensive washing with PBS, the cells were haptenized with DNBS
(4 mM, pH 8.0) for 30 min in serum-free RPMI, and then washed
with PBS containing 10% FCS. 1  105 ODN-treated and DNBS-
derivatized DC were injected s.c. in 200 mL of saline into the back
skin of naı¨ve BALB/C recipient mice. Five days later, the mice were
challenged by epicutaneous application of 0.2% DNFB on the ear.
One group of naı¨ve mice received untreated and unhaptenized-DC
injections at day 0 but were painted with DNFB on day 5 and
served as controls. Ear swelling was evaluated as described above.
Immunohistochemical analysis of mouse skin Skin samples
were collected from sensitized mice at 24 h after challenge. In
order to test for the effect of CpG ODN treatment on the phenotype
of skin DC, 20 mg of CpG ODN and control ODN (total volume of 50
mL) was injected intradermally in the right ear of naı¨ve mice 24 h
before epicutaneous application of a sensitizing dose of 0.5% of
DNFB onto the same ear. Ears were recovered 24 h after hapten
application and analyzed for expression of DC surface molecules.
Ears of mice were cut in two parts, and one-half was fixed in
10% formalin, embedded in paraffin and stained with hematoxylin
and eosin (H&E). The other half was frozen in OCT compound
(MILES Inc., Torrance, California). Frozen sections were fixed for 10
min in 41C acetone, air-dried, treated with 5% FCS in Tris-buffered
saline. Primary antibodies included: anti-CD80 mAb (RMMP-1,
Rat IgG2a) (Caltag Lab, Burlingame, California), anti-CD86 mAb
(PO3.1, Rat IgG2a), anti-MHC class II mAb (M5/114.15.2, Rat
IgG2b) (Pharmingen, San Diego, California), and anti-CD8 mAb
(KT-15, Rat IgG2a) (Harlan Sera-Lab, Loughborough, UK). After
washing, slides were incubated with biotinylated rabbit anti-rat IgG
(Hþ L) secondary Ab (Vector Burlingame, California). Slides were
next incubated with biotinylated alkaline phosphatase–streptavidin
(Strept ABComplex/AP, Dako, Lavoratories, Glostrup, Denmark), and
the reaction was developed using BCIP/NBT (Bio-Rad, Hercules,
California), followed by counterstaining with nuclear fast red. Irrel-
evant rat IgG mAbs (Caltag Lab) were used as primary antibody to
confirm the specificity of immunostaining. In some experiments,
sections were further incubated with anti-CD3 mAb (145-2C11,
Hamster IgG1) (Pharmingen), and then HRP-conjugated anti-
Figure 6
Cytidine–phosphate–guanosine–oligodeoxynucleotides (CpG ODN)
enhance the ability of cultured dendritic cells (DC) to transfer con-
tact hypersensitivity (CHS) to 2,4-dinitrofluorobenzene (DNFB). Skin
DC recovered from naı¨ve mice were treated in vitro with CpG ODN (A),
control ODN (B) (1 mM at 371C for 12 h), or medium alone (C), and then
haptenized with 2,4-dinitrobenzenesulfonic acid (DNBS) (4 mM DNBS
at 371C for 30 min). Cells were transferred to recipient naı¨ve mice
(subcutaneous back skin injection of 1  105 DC per mouse). Five days
later, recipient mice were challenged with DNFB (10 mL of 0.2% DNFB
on the ear) and CHS was determined by ear swelling at 24 h post-
challenge. Controls included mice which received untreated/unhap-
tenized DC at day 0 and DNFB painting on the ear at day 5 (D). CpG
ODN/DNBS-derivatized DC-transferred mice showed a significantly
enhanced CHS response. Results are expressed as the mean ear
swelling  SD. p (o0.05) indicates statistical significance compared with
mice which received the control ODN/DNBS-derivatized DC. The result is
one representative experiment of three (consisting of 5 mice per group).
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hamster IgG (Hþ L) Ab (Santa Cruz Biotechnology, Santa Cruz, Cal-
ifornia). Specific binding was revealed with 3-amino-9-ethylcarbazole
(AEC) (Dako). Semi-quantitative analysis of stained cells was done by
counting the number of positive cells in epidermis per 5 mm of de-
rmo-epidermal (D-E) junction of two different sections. Results rep-
resent the mean number of positive cells per mm of D-E junction.
RNA extraction and RT-PCR analysis of CD8 and IFN-c
mRNA At 24 h after challenge, ear samples were collected from
CpG ODN- or control ODN-treated and sensitized mice, and frozen
in liquid nitrogen. Total RNA extracted using a SV Total RNA Iso-
lation System (Promega, Madison, Wisconsin) was reverse tran-
scribed using poly dT15 primers and Superscript II RT (Invitrogen,
Carlsbad, California) (90 min 371C). The amount of RNA to be used
for the detection was normalized using the housekeeping gene
HPRT (hypoxanthine phosphoribosyltransferase) as reference as
previously described (Akiba et al, 2002). The cDNA obtained was
amplified using different sets of primers, for HPRT (50 primer: 50
GTA ATG ATC AGT CAA CGG GGG AC 30-30 primer: 50 CCA GCA
AGC TTG CAA CCT TAA CCA 30) for CD8 (50 primer: 50 AGG ATG
CTC TTG GCT CTT CC 30-30 primer: 50 TCA CAG GCG AAG TCC
AAT CC 30) for IFN-g (50 primer: 50 GCT CTG AGA CAA TGA ACG
CT 30-30 primer: 50 AAA GAG ATA ATC TGG CTC TGC 30). The
amplifications were carried out with 29 cycles for HPRT and 33
cycles for IFN-g and CD8 (1 min at 941C, 1 min 30 s at 601C, 2 min
at 721C). The PCR products were subjected to gel electrophoresis
using ethidium-containing 1.5% agarose gel, and visualized by UV
light. To evaluate the mRNA expression, we measured the signal
intensities of HPRT, CD8, and IFN-g by densitometry and com-
pared their arbitrary densitometric units. The results were ex-
pressed as ratios of optical densities (OD) to HPRT band. We
confirmed that the mRNA levels could be compared in the linear
range under the conditions mentioned above.
Statistical analysis All experimental groups consisted of five
mice, and all experiments were performed at least three times. The
statistical significance of differences between mean values of
groups was evaluated with the one-way factorial ANOVA (po0.05).
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